Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Counter-Regulatory Renin-Angiotensin System: An Important Line of Research to Understand and Limit the Severity of COVID-19

Author(s): Cédric Annweiler*, Zhijian Cao, Nicolas Papon, Hervé Kovacic and Jean-Marc Sabatier

Volume 22, Issue 2, 2022

Published on: 10 September, 2021

Article ID: e100921196331 Pages: 3

DOI: 10.2174/1871526521666210910063227

[1]
Kidde J, Sahebkar A. From Foe to Friend in COVID-19: RAS Inhibitors. J Infect Dis 2020. [Epub ahead of print]
[http://dx.doi.org/10.1093/infdis/jiaa629]
[2]
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020; 382: 1653-9.
[3]
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581: 215-20.
[4]
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444-8.
[5]
Annweiler C, Bourgeais A, Faucon E, Cao Z, Wu Y, Sabatier JM. Neurological, Cognitive, and Behavioral Disorders during COVID-19: The Nitric Oxide Track. J Am Geriatr Soc 2020; 68: 1922-3.
[6]
Ocaranza MP, Riquelme JA, Garcia L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nature Rev Card 2020; 17: 116-29.

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy